cyrilzakka/clinical-trials huggingface dataset:
Facilitating Needle Alignment With Aiming Method

Although ultrasound-guided catheterization of the subclavian vein is becoming standard procedure in anesthetic practice, failure to align the needle and the transducer still can lead to possibly complications. In this study, we proposed a new alignment method, namely Aiming Method. The purpose of this study is to investigate whether the use of this aiming method improved resident volunteers' performance of ultrasound-guided SC insertion in real patients. Specifically, residents were asked to perform three different methods: landmark techniques, ultrasound-guided with aiming method and ultrasound-guided plus needle guide techniques.


Eligibility Criteria:
Inclusion Criteria:

* 18 years to 70 years
* American Society of Anesthesiologists (ASA) Physical Status Ⅰ-Ⅲ
* Elective surgery patients requiring subclavian vein catheterization

Exclusion Criteria:

* Local anatomic abnormalities in subclavicular area
* Preexisting subclavian vein thrombosis or coagulation disorders
* Refusal of subclavian vein catheterization
The Effect of a Bioactive Fabric Sleeve

In-season pitch volume have been shown to relate to arm soreness in collegiate baseball players. Arm soreness is a common ailment following a pitching appearance due to the adaptation to soft tissue in response to a repetitive load to the throwing arm. Specifically, ongoing and accumulated fatigue and soreness to the flexor pronator mass region of the arm may be a predecessor for UCL injury. Different recovery modalities such as a bioactive fabric sleeve may give pitchers a recovery advantage throughout a baseball season. The primary purpose of this study is to determine if there is a difference in subjective soreness of the flexor pronator mass the day following a game pitching appearance using a sleeve with bioactive fabric which potentially improves cellular function versus a control sleeve.


Eligibility Criteria:
Inclusion Criteria:

* Stanford Baseball Player

Exclusion Criteria:

* None
Morehouse Total Cancer Care Protocol

The overall objective of the Morehouse Total Cancer Care study is to develop an improved standard of cancer care by facilitating new biomarker and drug target discovery, informatics solutions, clinical trials, and "personalized medicine" for our community oncology partners (i.e., community hospital systems, and other cancer care providers). To bring new translational research to the community, Morehouse School of Medicine has initiated the Total Cancer Care Program (TCCP). The TCCP establishes a unique collection of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) from thousands of African American cancer patients, survivors, or those at risk of having cancer. This is not a treatment trial, but a longitudinal study designed to create a centralized cancer biorepository for precision medicine.

Through this protocol, Morehouse School of Medicine and its partners will establish and maintain a unique repository of blood, tissue, other biological samples and their associated data (survey data, medical records data, cancer registry data, and other related data) collected from thousands of patients 18 years of age or older who have cancer or are at risk of developing cancer. In this protocol, investigators require an informed consent of patients to study their answers to survey questions that may be collected as part of their regular clinical care, permission to study their medical and related records, and permission to collect excess tissues removed at the time of planned surgery, an additional tumor sampling (needle passes) at the time of planned diagnostic biopsies, previously collected, stored tumor tissue (if available), blood, and/or other biological samples. Additional research tumor samples may be collected at the time of any diagnostic needle biopsy or endoscopic biopsy or, if available, patient tissue from a previous procedure will be obtained and utilized as needed. Clinical and related data will be collected on all patients from the time of initial entry into the study and will continue for life.

Eligibility Criteria:
Inclusion Criteria:

1. 18 years of age and older.
2. Diagnosed with cancer, or at risk for cancer. This includes anyone in the general population, but our primary focus will be on patients with a cancer diagnosis.
3. Able to understand and sign the TCCP Informed Consent and Research Authorization form directly or through an authorized representative. The Informed Consent and Research Authorization will be available in both English and Spanish languages

Exclusion Criteria:

None

-
Study of Polymorphisms in pear1 Gene Link to Platelet Activation and Signaling Pathway Variations

In this study PEAR1 polymorphisms effects will be analyze in blood platelets to determine how PEAR1 regulates platelet activation.

Several large-scale studies have confirmed the long held notion that platelet responses to different agonists are highly variable, within well defined populations of healthy donors. Single nucleotide polymorphisms in genes encoding platelet proteins can explain the wide range of responses to standard platelet agonists. Yet, numerous SNPs point towards proteins with previously unknown function in platelets, wich modulate the complex network of signaling events that regulate platelet function and further augment variability. PEAR1 is mainly expressed in platelets and endothelial cells. A few studies have linked SNPs in PEAR1 with decreased or increased platelet responses to various agonists. However, hitherto, no direct functional studies have been carried out to determine whether and how PEAR1 modulate intracellular signaling pathways relevant for platelet function.

Eligibility Criteria:
Inclusion Criteria:

* healthy voluntary donors

Exclusion Criteria:

* none
Development of a Mobile System for Self-management of Schizophrenia (SOS)

This 2-arm clinical trial piloted a mobile Self-Management of Schizophrenia (SOS) system that administers interventions targeting persistent symptoms of psychosis, social dysfunction, and medication adherence. Researchers compared an intervention arm using the SOS system and an arm receiving treatment as usual on the outcomes of change in severity of psychotic symptoms and change in social functioning.


Eligibility Criteria:
Inclusion Criteria:

* DSM-IV (Diagnostic and Statistical Manual IV) criteria for schizophrenia or schizoaffective disorder based on a chart diagnosis;
* 18 years or older;
* Prescribed oral antipsychotic medication; and
* A rating of "3" or lower on one of the three items which comprise the Domination by Symptoms factor from the Recovery Assessment Scale, indicating patient-rated need for illness self-management

Exclusion Criteria:

* Hearing, vision, or motor impairment that make it impossible to operate a smartphone or respond to prompts (determined using demonstration smartphone for screening); and
* English reading level below 4th grade (determined using the Wide Range Achievement Test - 4th Edition)
Treatment Clinical Practice in Bipolar Depression in Spain

Cross-sectional observational, non interventional, multicenter study of retrospective review of clinical records of ambulatory followed up bipolar patients in order to record epidemiological aspects of the course of the disorder, more specifically of bipolar depression episodes and the clinical practices carried out by psychiatrists in Spain in bipolar depressive episodes


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed of Bipolar Disorder I or II (DSM-IV-TR) in ambulatory follow-up
* Evolution of the bipolar diagnoses inferior to 10 years
* Having recorded in the patient's clinical history the clinical management of at least two bipolar depressive episodes

Exclusion Criteria:

* Not having enough information recorded in the clinical history for the essential measurement variables
* To have taken part in other study in the last 6 months
Position and Esophageal Pressure

Esophageal pressure measurements are used in moderate/severe Accurate Respiratory Distress SyndromeARDS patients in order to set ventilator settings. There might be variations of the measured value according to the patient position (0° vs 30°) at the time of measurements.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Acute respiratory failure defined by PaO2/FIO2\< 300 mmHg or pH\<7,35 and pCO2\>45mmHg or Moderate or severe Accurate Respiratory Distress Syndrome ARDS defined by:

  * New or worsening respiratory symptoms in the previous week.
  * Bilateral opacities-not fully explained by effusions, lobar/lung collapse, or Nodules
  * Respiratory failure not fully explained by cardiac failure or fluid overload
  * PaO2/FIO2\< 200 mmHg and PEEP ≥ 5 cm H2O and VT ≤6 ml/kg of Ideal Body Weight
* Patient intubated or tracheotomized and receiving mechanical ventilation
* Indication of esophageal measurement decided by the clinician

Exclusion Criteria:

* Contraindication to naso-gastric tube insertion :

  * Recent gastro-duodenal ulcer
  * Stage III esophageal varices
* Refractory intracranial hypertension
* Unstabilized spine fracture
* Surgical contraindication
* Burns on more than 20 % of the body surface
* Underlying disease with a life expectancy of less than one year
* End-of-life decision before inclusion
* Pregnant or breast-feeding patients
* Subject deprived of freedom, minor, subject under a legal protective measure
* Research team unavailability
* Lack of medical care plan
Design and Evaluation of an In-Vehicle Real-Time Drunk Driving Detection System

To analyze driving behavior of individuals under the influence of alcohol while driving in a real car. Based on the in-vehicle variables, the investigators aim at establishing algorithms capable of discriminating sober and drunk driving using machine learning.

Driving under the influence of alcohol (or "drunk driving") is one of the most significant causes of traffic accidents. Alcohol consumption impairs neurocognitive and psychomotor function and has been shown to be associated with an increased risk of driving accidents. However, autonomous driving (level 4 or 5) is likely to be broadly available only at a substantially later time point than previously thought due to increasing concerns of safety associated with this technology. Therefore, solutions bridging the upcoming time period by more rapidly and directly addressing the problem of drunk driving associated traffic incidents are urgently needed.

On the supposition that driving behavior differs significantly between sober state and drunk state, the investigators assume that different driving patterns of people under alcohol influence compared to sober states can be used to generate drunk driving detection models using machine learning algorithms. In this study, driving for data collection is initially performed at a sober baseline state (no alcohol) and then after alcohol administration (with a target of 0.15 mg/l and 0.35 mg/l breath alcohol concentration).

Eligibility Criteria:
Inclusion Criteria:

* Informed consent as documented by signature.
* In possession of a definite Swiss or EU driving license.
* At least 21 years old
* Active driving in the last 6 months.
* No special equipment needed when driving.
* Drinks alcohol at least occasionally (moderate/social consumption).
* Fluent in (Swiss) German and no speech impairment.

Exclusion Criteria:

* Health concerns that are incompatible with alcohol consumption.
* Any potential participant currently taking illegal drugs or medications that interact with alcohol.
* Women who are pregnant or breast feeding.
* Intention to become pregnant during the course of the study.
* Teetotallers (alcohol abstinent persons).
* Alcohol misuse (excessive alcohol consumption habits/risky drinking behaviour (according to WHO definition) and/or the biomarker PEth in capillary blood \> 200 ng/mL at first visit.
* Known or suspected drug abuse within 4 weeks before the study (e.g., positive urine drug test at first visit).
* Non-compliance to alcohol abstinence within 24 hours before the study visits.
* Inability to follow the procedures of the study, e.g., due to language problems, psychological disorders, dementia, etc. of the participant.
* Participation in another study with investigational drug within the 30 days preceding and during the present study.
Acute Effects of Vibration on Shoulder Flexibility - Experimental Controlled Trial

Whole body vibration (WBV) can help to improve muscle flexibility by stimulating the neuromuscular functions. But there is a dearth in the literature to prove its effectiveness in improving the flexibility of the upper limb muscles. Therefore the purpose of the study is to determine the effects of vibration on improving upper limb flexibility. This experimental research will be conducted by recruiting participants at the age of 19 to 27 with no histories of injuries on the upper limb. They will be randomly assigned into two groups; experimental (with vibration) and control (no vibration) group. The WBV machine will be used to provide vibration to the upper extremities by placing both palms on the vibration platform. The outcome measure of active chest flexibility and shoulder reach flexibility will be performed pre and post vibration.


Eligibility Criteria:
Inclusion Criteria:

* ages of 19 to 28
* no athletic background

Exclusion Criteria:

* shoulder pain and injury within 12 months, recent back pain and neck pain, recent fever and high blood pressure.
Evaluation of Oral and Maxillofacial Swellings by Ultrasonographic Features

Fifty patients were randomly selected with oral and/or maxillofacial swelling, thorough case history and clinical examination were done, then ultrasound examinations were done for all of them and they were classified into five groups (I. inflammatory/space infection and abscess swellings), (II. cystic swellings), (III. lymph node swellings), (IV. benign swellings) and (V. malignant neoplastic swellings) according to their ultrasound features. The patients were subjected to histopathologic evaluation.

Fifty patients with swellings in the oral and/or maxillofacial region were randomly selected. Any other swellings that were caused by trauma and/or fracture, extended below the neck or patient reluctant to undergo US were excluded from the study. This study was approved by the (Research Ethics Committee) (REC), Faculty of Dentistry, Minia University before starting the research and all the entire patients had signed a standardized informed consent laid down by REC.

A comprehensive questionnaire was used to assess history and through extra-oral \& intra-oral examinations were carried out and recorded on the basis of criteria reported by Das.11 The ultrasonographic investigations were carried using an ultrasound diagnostic modality (LOGIQ- P5) (GE Medical System, Korea) with color Doppler function by using a linear array transducer, operating at a frequency of (7.5-12 MHz). All the examinations were performed over the swellings and also compared to the contra-lateral/normal side whenever needed. (Fig. 1) All sonographic images were interpreted by an expert sonologist (15 years experience) and US features were recorded to extract ultrasonographic guided (USG) diagnosis and patient's swellings were categorized into five groups: inflammatory/infection/abscess swellings (Group I), cystic swellings (Group II), lymph node swellings (Group III), benign swellings (Group IV) and malignant neoplastic swellings (Group V).12 Finally, the included patients were subjected to either fine needle aspiration cytology (FNAC) or surgical intervention for histopathological examination to extract the histopathological diagnosis

Eligibility Criteria:
Inclusion Criteria:

* All with oral and/or maxillofacial swelling,

Exclusion Criteria:

* Any other swellings that were caused by trauma and/or fracture, extended below the neck or patient reluctant to undergo US were excluded from the study.
PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

PROMISE aims to create a comprehensive nationwide registry of prostate cancer patients with germline pathogenic variants by prospectively screening approximately 5,000 subjects with a confirmed prostate cancer diagnosis, either through tissue biopsy, PSA greater than 100 ng/dL and/or radiographic evidence of disease and receiving systemic therapy for prostate cancer. Patients at all stages of disease will be welcome to participate in the PROMISE Registry.

Participants will be recruited \& screened over a five-year period. Study participants will be asked to provide a saliva sample to be tested for germline cancer risk variants through Color Health. If the results identify a pathogenic or likely pathogenic variant, an appointment with a genetic counselor from Color Health will be scheduled to discuss the results.

Participants will complete a baseline demographic survey that includes self-reported health history, family history of cancer and standardized patient reported outcome (PRO) measures.

PROMISE Registry staff will request medical records from the participant's cancer care provider(s) for the purpose of obtaining clinical data.

Participants will receive bi-annual newsletters offering information on new developments in treatment and research opportunities, including clinical trials, associated with genetic variants.

Eligible participants (those with target germline mutations) will be followed every 6 months to obtain updated health records data and patient-reported outcomes data. Participants will be followed for a minimum of 15 years.

The PROMISE registry will help identify prostate cancer patients with pathogenic variants to learn more about how these variants affect patient outcomes. Ultimately, we hope to help patients learn more about their disease and the treatments that they may derive the most benefit from, including the germline genetic biomarker-based clinical trials they may be eligible for.

For more information, visit the study website at: prostatecancerpromise.org


Eligibility Criteria:
Inclusion Criteria:

* Have prostate cancer (any stage of disease or survivorship) diagnosed or documented through one of the following:

  * tissue biopsy, and/or
  * PSA greater than 100 ng/dL (1ng/ml), and/or
  * clear radiographic evidence of disease
* Live in the United States (including Puerto Rico, Guam, American Samoa, US Virgin Islands, Northern Mariana Islands)

Exclusion Criteria:

* Unable or unwilling to provide all of the necessary information for eligibility
* Incomplete inclusion criteria
The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy

During early postoperative after lung resection surgery, patients without oxygen supplementation may experience hypoxemia. Oxygen supplementation can be given via oxygen mask or cannular. In this study the investigators want to the sudy the effect of oxygen supplementation via oxygen cannular during the first 120 minutes after surgery


Eligibility Criteria:
Inclusion Criteria:

* age =/\> 18 years
* lobectomy or pneumonectomy or wedge resection
* ASA 1-3
* preoperative oxygen saturation \< 95 %
* receiving epidural analgesia

Exclusion Criteria:

- cannot communication
A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

The main purpose of this study is to evaluate the effects of multiple doses of LY3537982 on the pharmacokinetics (PK) of digoxin (a P-glycoprotein \[P-gp\] substrate), rosuvastatin (a breast cancer resistance protein \[BCRP)\] substrate), and midazolam (a substrate of Cytochrome P450 3A4 \[CYP3A4\]) in adult healthy participants. The study will also evaluate the safety and tolerability of LY3537982 with or without single doses of digoxin, rosuvastatin, and midazolam. The study is conducted in two parts. Participants will stay in the research center during the study, which will last about 23 and 11 days for part 1 and part 2, respectively, not including screening.


Eligibility Criteria:
Inclusion Criteria:

* Healthy status as defined by the absence of evidence of any clinically significant active or chronic disease
* Body mass index (BMI): 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

Exclusion Criteria:

* Females who are lactating or of childbearing potential
* Clinically significant history of any drug sensitivity, drug allergy, or food allergy
Family-based and Adolescent Residential Drug Treatment

The fundamental objective of this study is to compare the effectiveness of an intensive in-home family-based treatment, Multidimensional Family Therapy, with a multifaceted residential treatment, Adolescent Residential Treatment, over 4 years post-intake and to delineate the mechanisms of change for each treatment. The study targets dually- diagnosed adolescent drug abusers recommended for residential treatment.

Aim 1: To compare the effectiveness of residential treatment with outpatient, family-based treatment multiple outcomes including substance use, mental health, school functioning, family function and delinquency among dually diagnosed adolescents.

Hypothesis 1. From intake to 2 months, residential treatment will show better outcomes than the family based treatment. Between 2 months and 18 months, family based treatment will show better outcomes than residential. Between 18 months and four years post intake, outpatient family based treatment will maintain its treatment gains, while the residential treatment condition will show an increase in these same symptoms and behaviors.

Aim 2: To examine the relationship between predictors (family, peer, educational/vocational functioning and involvement in post-treatment services), and outcomes (drug use, co-morbid symptoms, and criminal behavior) during the four-year post intake period.

Hypothesis 2a. Family functioning, educational/vocational functioning, and peer relationships measured at discharge will predict drug use, co-morbid symptoms, and criminal behaviors though the four year longer term follow up period.

Hypothesis 2b. Family functioning, educational/vocational functioning, peer relationships, and involvement in post-treatment services during the post treatment period will predict drug use, co-morbid symptoms, and criminal behavior through the longer term follow up period.

Research Question 1. Is the rate of change in family functioning, educational/vocational functioning, peer relationships, and involvement in post-treatment services related to the rate of change in drug use, co-morbid symptoms, and criminal behavior?

Eligibility Criteria:
Inclusion Criteria:

* Youth between the ages of 13 and 17
* Referred to ATP for residential substance abuse treatment in youth dual diagnosis program
* Dually diagnosed for substance abuse or dependence and at least one of the following co-morbid conditions: major depressive disorder, bipolar disorder, I conduct disorder, oppositional defiant disorder,
* At least one parent or parent-figure can be located at the time of referral.
* Obtain informed consent from a parent or formal guardian and assent from youth to participate in the study.

Exclusion Criteria:

* Have any of the following disorders: Mental Retardation, Eating Disorders, Schizophrenia, or Pervasive Developmental Disorders.
* Current suicidality.